Goodwin’s Life Sciences team advised Dimension Therapeutics on its definitive agreement to be acquired by Ultragenyx Pharmaceutical, a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases. Ultragenyx will acquire all of the outstanding shares of common stock of Dimension for $6.00 per share, or approximately $151 million in cash, based on currently outstanding shares. The transaction is structured as a tender offer and will be funded through Ultragenyx’s existing cash resources. The tender offer is not subject to a financing condition and is expected to close before the end of 2017. The transaction is a compelling opportunity to create value as it combines Dimension’s innovative portfolio of assets and its advanced gene therapy platform with Ultragenyx’s late-stage clinical, regulatory and commercial expertise in the rare disease space.
The agreement between Ultragenyx and Dimension has been approved by the boards of directors of both companies, and follows the termination of the merger agreement between Dimension Therapeutics and REGENXBIO Inc.
Dimension Therapeutics is a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus gene delivery technology.
The Goodwin team was led by partners Kingsley Taft and Andrew Goodman and included partner James Matarese and associates Lillian Kim, Tobias Schad and Catherine Magazu (Life Sciences); counsel Kathleen Kean and associate Noelle Dubiansky (Intellectual Property); partner Janet Andolina and associate Todd Pollock (Tax); partner Natascha George; counsel Stephanie Philbin (FDA Regulation); partner Jennifer Fay and associate Christina Bitter (Labor and Employment); counsel Kirby Lewis (Antitrust); counsel Jacqueline Klosek (Privacy); and partner Deborah Birnbach (Litigation).
For additional details on the transaction, please read the press release.